vs
Apellis Pharmaceuticals, Inc.（APLS）与PTC THERAPEUTICS, INC.（PTCT）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是PTC THERAPEUTICS, INC.的1.2倍（$199.9M vs $164.7M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -82.0%，领先52.5%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -22.7%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-36.6M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -11.5%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
PTC Therapeutics是一家总部位于美国的制药企业，专注于开发口服小分子药物及基因疗法，通过靶向转录后调控机制调节基因表达，相关产品管线主要面向罕见病治疗领域，致力于满足相关疾病未被覆盖的临床治疗需求。
APLS vs PTCT — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $164.7M |
| 净利润 | $-59.0M | $-135.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -43.3% |
| 净利率 | -29.5% | -82.0% |
| 营收同比 | -5.9% | -22.7% |
| 净利润同比 | -62.2% | -104.8% |
| 每股收益（稀释后） | $-0.40 | $-1.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $164.7M | ||
| Q3 25 | $458.6M | $211.0M | ||
| Q2 25 | $178.5M | $178.9M | ||
| Q1 25 | $166.8M | $1.2B | ||
| Q4 24 | $212.5M | $213.2M | ||
| Q3 24 | $196.8M | $196.8M | ||
| Q2 24 | $199.7M | $186.7M | ||
| Q1 24 | $172.3M | $210.1M |
| Q4 25 | $-59.0M | $-135.0M | ||
| Q3 25 | $215.7M | $15.9M | ||
| Q2 25 | $-42.2M | $-64.8M | ||
| Q1 25 | $-92.2M | $866.6M | ||
| Q4 24 | $-36.4M | $-65.9M | ||
| Q3 24 | $-57.4M | $-106.7M | ||
| Q2 24 | $-37.7M | $-99.2M | ||
| Q1 24 | $-66.4M | $-91.6M |
| Q4 25 | -25.6% | -43.3% | ||
| Q3 25 | 48.7% | 1.4% | ||
| Q2 25 | -18.6% | -19.5% | ||
| Q1 25 | -50.0% | 82.5% | ||
| Q4 24 | -12.3% | -76.2% | ||
| Q3 24 | -24.0% | -27.7% | ||
| Q2 24 | -14.7% | -21.5% | ||
| Q1 24 | -36.0% | -21.6% |
| Q4 25 | -29.5% | -82.0% | ||
| Q3 25 | 47.0% | 7.5% | ||
| Q2 25 | -23.6% | -36.3% | ||
| Q1 25 | -55.3% | 73.7% | ||
| Q4 24 | -17.1% | -30.9% | ||
| Q3 24 | -29.2% | -54.2% | ||
| Q2 24 | -18.9% | -53.1% | ||
| Q1 24 | -38.5% | -43.6% |
| Q4 25 | $-0.40 | $-1.63 | ||
| Q3 25 | $1.67 | $0.20 | ||
| Q2 25 | $-0.33 | $-0.83 | ||
| Q1 25 | $-0.74 | $10.04 | ||
| Q4 24 | $-0.30 | $-0.85 | ||
| Q3 24 | $-0.46 | $-1.39 | ||
| Q2 24 | $-0.30 | $-1.29 | ||
| Q1 24 | $-0.54 | $-1.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $1.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $-205.3M |
| 总资产 | $1.1B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $1.9B | ||
| Q3 25 | $479.2M | $1.7B | ||
| Q2 25 | $370.0M | $2.0B | ||
| Q1 25 | $358.4M | $2.0B | ||
| Q4 24 | $411.3M | $1.1B | ||
| Q3 24 | $396.9M | $1.0B | ||
| Q2 24 | $360.1M | $1.1B | ||
| Q1 24 | $325.9M | $884.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $-205.3M | ||
| Q3 25 | $401.2M | $-155.8M | ||
| Q2 25 | $156.3M | $-206.5M | ||
| Q1 25 | $164.2M | $-185.8M | ||
| Q4 24 | $228.5M | $-1.1B | ||
| Q3 24 | $237.1M | $-1.1B | ||
| Q2 24 | $264.3M | $-980.2M | ||
| Q1 24 | $266.7M | $-893.9M |
| Q4 25 | $1.1B | $2.9B | ||
| Q3 25 | $1.1B | $2.6B | ||
| Q2 25 | $821.4M | $2.6B | ||
| Q1 25 | $807.3M | $2.7B | ||
| Q4 24 | $885.1M | $1.7B | ||
| Q3 24 | $901.9M | $1.8B | ||
| Q2 24 | $904.5M | $1.9B | ||
| Q1 24 | $831.9M | $1.8B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-34.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-36.6M |
| 自由现金流率自由现金流/营收 | -7.1% | -22.3% |
| 资本支出强度资本支出/营收 | 0.1% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $702.3M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $-34.3M | ||
| Q3 25 | $108.5M | $-66.3M | ||
| Q2 25 | $4.4M | $-58.3M | ||
| Q1 25 | $-53.4M | $870.1M | ||
| Q4 24 | $19.4M | $-30.0M | ||
| Q3 24 | $34.1M | $-77.0M | ||
| Q2 24 | $-8.3M | $-71.5M | ||
| Q1 24 | $-133.0M | $70.8M |
| Q4 25 | $-14.3M | $-36.6M | ||
| Q3 25 | $108.3M | $-69.7M | ||
| Q2 25 | $4.4M | $-59.6M | ||
| Q1 25 | $-53.4M | $868.4M | ||
| Q4 24 | $19.3M | $-33.8M | ||
| Q3 24 | — | $-77.5M | ||
| Q2 24 | $-8.4M | $-78.8M | ||
| Q1 24 | $-133.3M | $61.2M |
| Q4 25 | -7.1% | -22.3% | ||
| Q3 25 | 23.6% | -33.1% | ||
| Q2 25 | 2.5% | -33.3% | ||
| Q1 25 | -32.0% | 73.8% | ||
| Q4 24 | 9.1% | -15.8% | ||
| Q3 24 | — | -39.4% | ||
| Q2 24 | -4.2% | -42.2% | ||
| Q1 24 | -77.3% | 29.1% |
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 4.0% | ||
| Q1 24 | 0.2% | 4.6% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | -4.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PTCT
暂无分部数据
